Latest Safety News

Select Harvests Limited delivered a robust FY2025 with net profit soaring to $31.8 million and net debt slashed by over 50%, despite a smaller almond crop. Strategic investments in processing and sales underpin a confident outlook.

Syntara Limited has successfully completed Phase 1a trials for its topical anti-fibrotic drug SNT-9465, demonstrating dose-dependent target engagement and safety, and is now progressing to an innovative Phase 1b study in hypertrophic scars.

Aura Energy’s 2025 AGM highlights strong uranium market fundamentals and strategic progress on its Tiris Project, despite some engineering delays. The company also strengthens its board and deepens ties in Mauritania as it prepares for production.

Monadelphous has reported a record-breaking year with $2.3 billion in new contracts and a strong financial performance, underpinned by strategic acquisitions and growth in energy transition sectors.

Monadelphous Group Limited reported a robust FY25 with record contract wins and a 30% revenue surge, setting the stage for continued growth in FY26. The company’s strategic acquisitions and energy transition focus underpin its optimistic outlook.

Renascor Resources has hit key construction milestones at its Australian Government co-funded Purified Spherical Graphite (PSG) demonstration facility, maintaining schedule for on-site commissioning this quarter. The project aims to establish a competitive, HF-free PSG supply chain outside China.

Aroa Biosurgery reported a 14% rise in product sales to NZ$44.6 million for the half-year ended September 2025, driven by strong growth in its Myriad portfolio. The company also posted a normalised EBITDA profit and reaffirmed its FY26 revenue and profit guidance.

Chimeric Therapeutics has received a $4.5 million R&D tax incentive refund from the Australian Government, underscoring its ongoing investment in innovative cancer cell therapies.

Cynata Therapeutics has completed the final patient visit in its Phase 3 trial for CYP-004, targeting knee osteoarthritis, with results expected in mid-2026. This milestone advances hopes for a disease-modifying therapy in a market desperate for new options.

PYC Therapeutics has secured Safety Review Committee approval to escalate dosing in its clinical trial for PYC-003, an RNA therapy targeting Polycystic Kidney Disease. This milestone moves the drug closer to pivotal Phase 2/3 trials.

Verbrec Limited has reported a strong FY2025 with record margins and resumed dividend payments after more than a decade, alongside strategic moves including a key acquisition and divestment.

Genesis Minerals has secured crucial rail agreements that clear the path for developing the Tower Hill open pit gold mine and expanding the Leonora mill, targeting first ore in FY28.